GlassScriptPhysician profile
Grigor A Badalyan
NPI 1699896571
$1,249.40
in general payments reported to CMS, 2019-2025
13 companies · $25.34 in 2025
The $25.34 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $142 · 2022: $122 · 2023: $203 · 2024: $757 · 2025: $25.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $498 · Travel and Lodging: $488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $497.58 |
| Travel and Lodging | $488.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $782.62 | 2024-2025 | Illumisite |
| Galvanize Therapeutics, INC | $109.09 | 2023 | Aliya System |
| Intuitive Surgical, INC. | $99.18 | 2021 | |
| Insmed, INC. | $67.60 | 2022-2023 | Arikayce |
| Baxter Healthcare | $32.53 | 2022 | |
| Novartis Pharmaceuticals Corporation | $28.64 | 2022-2023 | |
| Genzyme Corporation | $24.47 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $18.89 | 2022 | |
| Genentech USA, INC. | $18.76 | 2022 | |
| Merck Sharp & Dohme LLC | $18.50 | 2023 | Belsomra |
| Glaxosmithkline, LLC. | $18.27 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $17.69 | 2023 | Tezspire |
| Pulmonx Corporation | $13.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grigor Badalyan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.